A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.

被引：2
|
作者：
Beatty, G. L.
Chiorean, E. G.
Torigian, D. A.
Teitelbaum, U. R.
Sun, W.
Fly, K. D.
Huhn, R. D.
Vonderheide, R. H.
O'Dwyer, P. J.
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Pfizer Inc, New London, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2539
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Huang, Alex C.
    Sullivan, Brendan
    Richman, Lee P.
    Torigian, Drew A.
    George, Sangeeth M.
    Stelekati, Erietta
    Chen, Fang
    Melenhorst, J. Joseph
    Lacey, Simon F.
    Xu, Xiaowei
    Wherry, E. John
    Gangadhar, Tara C.
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    Vonderheide, Robert H.
    ONCOIMMUNOLOGY, 2018, 7 (10):
  • [32] Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
    U Graeven
    B Kremer
    Th Südhoff
    B Killing
    F Rojo
    D Weber
    J Tillner
    C Ünal
    W Schmiegel
    British Journal of Cancer, 2006, 94 : 1293 - 1299
  • [33] Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
    Graeven, U
    Kremer, B
    Südhoff, T
    Killing, B
    Rojo, F
    Weber, D
    Tillner, J
    Ünal, C
    Schmiegel, W
    BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1293 - 1299
  • [34] PHASE 1 DEVELOPMENT OF RAVAGALIMAB, AN ANTI CD40 MONOCLONAL ANTIBODY, TO SUPPORT DOSE SELECTION FOR PHASE 2
    Bhatnagar, S.
    Hao, S.
    Hew, K.
    Nader, A.
    Ismail, M.
    Doan, T.
    Lazar, A.
    Mohamed, M.
    Liu, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S48 - S48
  • [35] CD40 Agonist Monoclonal Antibody-Mediated Hepatitis in TNF-Receptor 1 Gene Knockout Mice
    Raabe, Oksana
    Birchler, Thomas
    Rehrauer, Hubert
    Eppler, Elisabeth
    BIOMEDICINES, 2021, 9 (08)
  • [36] Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients
    Wattenberg, Max M.
    Herrera, Veronica M.
    Giannone, Michael A.
    Gladney, Whitney L.
    Carpenter, Erica L.
    Beatty, Gregory L.
    JCI INSIGHT, 2021, 6 (05)
  • [37] A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies
    Ba, Yi
    Zhang, Huilai
    Deng, Ting
    Ning, Tao
    Fan, Qian
    CANCER RESEARCH, 2024, 84 (07)
  • [38] A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
    Zhen, David Bing
    Griffith, Kent A.
    Ruch, Joshua Michael
    Morgan, Meredith
    Kim, Edward Jae-hoon
    Sahai, Vaibhav
    Simeone, Diane M.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [39] A phase 1b/2 study of CD40 agonistic monoclonal antibody (APX005M) together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic adenocarcinoma patients
    O'Hara, Mark
    Mick, Rosemarie
    Lyman, Jaclyn
    Xu, Jingying
    Hosseini, Maryam
    LaVallee, Theresa
    Gherardini, Pier Federico
    Vance, Barbara
    Trifan, Ovid
    Dugan, Ute
    Shalabi, Aiman
    Ibrahim, Ramy
    Vonderheide, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [40] Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
    Wang-Gillam, Andrea
    Lockhart, Albert C.
    Tan, Benjamin R.
    Suresh, Rama
    Singh, Preet Paul
    Lim, Kian-Huat
    Morton, Ashley
    Huffman, Jess
    Marquez, Samantha
    Boice, Nicolas
    DeNardo, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345